000170123 001__ 170123
000170123 005__ 20260318155255.0
000170123 0247_ $$2doi$$a10.1016/j.anpede.2021.04.008
000170123 0248_ $$2sideral$$a148538
000170123 037__ $$aART-2022-148538
000170123 041__ $$aeng
000170123 100__ $$aSánchez Malo, María José
000170123 245__ $$aGrowth hormone deficit: Influence of puberty on the response to treatment
000170123 260__ $$c2022
000170123 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170123 5203_ $$aIntroduction: Short stature is the most frequent reason for consultation in Pediatric Endocrinology consultations and sometimes requires treatment with growth hormone. The aim of the study was to analyze the response to treatment based on its onset in pubertal or prepubertal stages and to analyze the possible benefit of an early onset.
Patients and methods: Longitudinal, retrospective and observational study in 139 patients treated for idiopathic growth hormone deficiency up to adult height. Main variables studied: (a) genetic background: maternal, paternal and genetic height; (b) perinatal history; (c) anthropometry during follow-up and at pubertal onset: weight, height, body mass index; (d) variables during follow-up and at pubertal onset: growth rate, bone age and growth prognosis. Final response variables: adult height, adult height with respect to target height, adult height with respect to initial growth prediction, adult height with respect to initial height at the start of treatment and adult height with respect to height at pubertal onset.
Results: Total pubertal gain was 0.84 ± 0.6 SD. 61.9% of the patients started treatment with rhGH in prepuberty. The initiation of treatment in the prepubertal stage and a higher total pubertal gain are correlated with a better final height (P = 0.001 and r = 0.507, P = 0.00, respectively). Furthermore, a longer duration of treatment in pre-puberty is correlated with a better final response (r = 0.328, P = 0.00).
Conclusions: The start of treatment in the prepubertal stage and its longer duration during this period are determining factors to achieve a good long-term response. Total pubertal gain was greater in patients who started treatment in the pubertal stage.
000170123 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000170123 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170123 700__ $$aHidalgo Sanz, Juan
000170123 700__ $$aHernández Tejedor, Cristina
000170123 700__ $$aGarcía Ventura, María
000170123 700__ $$0(orcid)0000-0002-5750-7350$$aFerrer Lozano, Marta
000170123 700__ $$0(orcid)0000-0003-2832-2266$$aLabarta Aizpún, Jose Ignacio$$uUniversidad de Zaragoza
000170123 700__ $$0(orcid)0000-0002-2865-5813$$ade Arriba Muñoz, Antonio$$uUniversidad de Zaragoza
000170123 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000170123 773__ $$g96, 3 (2022), 221-229$$tAnales de Pediatría (English Edition)$$x2341-2879
000170123 8564_ $$s1172143$$uhttps://zaguan.unizar.es/record/170123/files/texto_completo.pdf$$yVersión publicada
000170123 8564_ $$s1814587$$uhttps://zaguan.unizar.es/record/170123/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170123 909CO $$ooai:zaguan.unizar.es:170123$$particulos$$pdriver
000170123 951__ $$a2026-03-18-13:52:46
000170123 980__ $$aARTICLE